# Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

> **NCT00006015** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** fluorouracil
- **DRUG:** leucovorin calcium
- **DRUG:** oxaliplatin

## Key facts

- **NCT ID:** NCT00006015
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-05
- **Primary completion:** 2002-12
- **Final completion:** 2003-02
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** lack of sufficient accrual
- **Last updated:** 2013-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006015, "Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00006015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*